Press Releases


Date   Headline
Jul 20, 2006 Cleveland BioLabs, Inc. Successfully Completes its Initial Public Offering
Jul 31, 2006 Cleveland BioLabs, Inc., Completes Analysis of Data Generated in a Primate Trial of Protectan CBLB502 Which Shows Unprecedented Increase in Survival Among Lethally Irradiated Animals
Aug 08, 2006 Cleveland BioLabs Reports Results of Non-Human Primate Trials of Its Lead Radioprotective Drug Candidate, Protectan CBLB502, at the 9th Annual Force Health Protection Conference
Aug 31, 2006 Cleveland BioLabs to Present at Roth Capital Partners Growth Stock Conference
Sep 06, 2006 National Cancer Institute Awards Cleveland BioLabs $750,000 Contract for Development of Radioprotectors
Sep 08, 2006 Cleveland BioLabs Retains Global Consulting Group as Investor Relations Counsel
Oct 20, 2006 Cleveland BioLabs To Present at Financial Services Exchange Conference
Oct 24, 2006 Cleveland BioLabs Signs Manufacturing Agreement With SynCo Bio Partners for Radiation Protection Compound
Oct 26, 2006 Cleveland BioLabs Appoints John Gordon, Ph.D. Director of Clinical Operations
Oct 26, 2006 Cleveland BioLabs Signs Manufacturing Agreement With SynCo Bio Partners for Radiation Protection Compound
Oct 26, 2006 Cleveland BioLabs President and CEO Provides Update on Clinical and Corporate Developments
Oct 26, 2006 CORRECTION: Cleveland BioLabs President and CEO Provides Update on Clinical and Corporate Developments
Oct 31, 2006 Cleveland BioLabs to Present at Rodman & Renshaw 8th Annual Healthcare Conference
Nov 01, 2006 Cleveland BioLabs Responds to Department of Health and Human Services Request for Information for Medical Countermeasures Against Bioterrorism Threats
Nov 06, 2006 Cleveland BioLabs Chief Scientific Officer to Co-Chair Symposium on Radioprotectants and Present at Radiation Research Society Meeting
Nov 09, 2006 Cleveland BioLabs Enters Contract Negotiations with Defense Threat Reduction Agency of Department of Defense for Developmental Grant
Nov 15, 2006 Cleveland BioLabs CEO Michael Fonstein, PhD, Interviewed by Wall Street Reporter
Nov 17, 2006 Cleveland BioLabs to Respond to Department of Defense 'Sources Sought Notice' for Therapeutic Products to Treat Gastrointestinal Effects of Acute Radiation Syndrome
Dec 01, 2006 Cleveland BioLabs Submits Response to Department of Defense 'Sources Sought Notice'
Dec 04, 2006 Cleveland BioLabs Initiates Phase II Hormone-Refractory Prostate Cancer Trial for Curaxin CBLC102
Dec 20, 2006 Cleveland BioLabs Highlights Department of Defense Presolicitation Notice of Request for Proposal for Medical Radiation Countermeasures to Treat Gastrointestinal Effects of Acute Radiation Syndrome
Jan 10, 2007 Cleveland BioLabs Protectans Technology Yields Stem Cell Research Breakthrough
Jan 12, 2007 Cleveland BioLabs Enters Strategic Partnership With Roswell Park Cancer Institute
Jan 23, 2007 Cleveland BioLabs Chief Scientist Andrei Gudkov Discusses Recent Stem Cell Discovery and Partnership With Roswell Park Cancer Institute With Firestocks.Com
Feb 05, 2007 Cleveland Biolabs Featured in Barron's
Feb 06, 2007 Cleveland BioLabs to Present at BIO CEO and Investor Conference
Feb 08, 2007 Cleveland BioLabs To Present at Roth Capital Partners 19th Annual OC Conference
Feb 08, 2007 Cleveland BioLabs Announces Annual Meeting
Mar 19, 2007 Cleveland BioLabs to Respond to Department of Defense Request for Proposal and Completes $30 Million Private Placement
Mar 20, 2007 Cleveland BioLabs Receives Developmental Grant from Department of Defense for Protectan CBLB502
Mar 26, 2007 Cleveland BioLabs to Present at ValueRich Small-Cap Financial Expo
Apr 04, 2007 Cleveland BioLabs Annual Meeting Update
Apr 05, 2007 Cleveland BioLabs Phase II Hormone-Refractory Prostate Cancer Trial Advances to Next Phase
Apr 09, 2007 Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival Benefits as Mitigator Against Radiation-Induced Damage in Study
Apr 13, 2007 WBB Securities Initiates Analyst Coverage of Cleveland BioLabs
Apr 16, 2007 Cleveland BioLabs President and CEO Reports Progress on Clinical and Corporate Developments
Apr 20, 2007 Cleveland BioLabs Protectan CBLB612 Demonstrates Efficacy in Stimulating Proliferation and Mobilization of Bone Marrow Stem Cells in Primate Model
Apr 23, 2007 Cleveland BioLabs Submits Response to Department of Defense Request for Proposal for Medical Radiation Countermeasures to Treat Gastrointestinal Effects of Acute Radiation Syndrome
Apr 27, 2007 Cleveland BioLabs to Present at Zangani Pharma Finance 2007 Conference
Apr 30, 2007 Cleveland BioLabs to Attend National Radiological Emergency Preparedness Conference
May 07, 2007 Firestocks.com Publishes Update on Cleveland BioLabs
May 17, 2007 Cleveland BioLabs to Present at 2007 Robins Emerging Opportunities Conference
May 21, 2007 Cleveland BioLabs Protectan CBLB612 Produces Breakthrough in Bone Marrow Stem Cell Transplant Study
May 23, 2007 Cleveland BioLabs to Present at Friedman Billings Ramsey 2007 Growth Conference
Jun 12, 2007 Cleveland BioLabs Set to Join Russell Microcap Index
Jul 17, 2007 Cleveland BioLabs Submits Responses to Two Requests for Information From Department of Health and Human Services and National Institute of Allergy and Infectious Diseases
Jul 25, 2007 Cleveland BioLabs to Present Protectan CBLB502 at 2007 BARDA Industry Day
Aug 06, 2007 European Journal of Immunology Paper Highlights Newly Discovered Properties of Cleveland BioLabs' Curaxin CBLC102
Aug 14, 2007 Cleveland BioLabs to Present at Noble Financial Conference
Aug 27, 2007 Cleveland BioLabs Announces Upgrade of Listing to NASDAQ Global Market
Aug 28, 2007 Cleveland BioLabs to Present at Roth Capital Partners 2007 New York Conference
Oct 18, 2007 Cleveland BioLabs Completes Manufacturing Process for Protectan CBLB502
Oct 22, 2007 Cleveland BioLabs to Present at Rodman & Renshaw 9th Annual Healthcare Conference
Oct 25, 2007 Cleveland BioLabs Celebrates Opening of Corporate Headquarters Building
Nov 09, 2007 Cleveland BioLabs Founding Partner Cleveland Clinic Receives Department of Defense Grant to Study Protectans CBLB502 and CBLB612 for Tourniquet and Other Battlefield Uses
Nov 15, 2007 Cleveland BioLabs to Present at 19th Annual Piper Jaffray Health Care Conference
Nov 26, 2007 Cleveland BioLabs Launches Phase II Advanced Renal Cell Carcinoma Trial for Curaxin CBLC102
Dec 04, 2007 Cleveland BioLabs Achieves Recovery From Neutropenia and Thrombocytopenia in Primates 48 Hours Post-Irradiation With Protectan CBLB502
Dec 06, 2007 Cleveland BioLabs to Present at NYSSA Biotech/Specialty Pharma Industry Conference
Dec 12, 2007 Cleveland BioLabs Protectan CBLB612 Outperforms Market Leading Hematopoietic Stem Cell Stimulator in Mouse Study
Dec 13, 2007 Cleveland BioLabs Recaps Development of Lead Compounds and Affirms Confidence in Competitive Position for Department of Defense Contract
Dec 17, 2007 Cleveland BioLabs to Postpone Year-End Update Conference Call
Jan 04, 2008 Cleveland BioLabs Not Selected for Defense Contract Award
Feb 07, 2008 Cleveland BioLabs CEO to Share Ongoing Development Strategy at BIO CEO and Investor Conference
Feb 08, 2008 Cleveland BioLabs Announces Annual Meeting
Feb 14, 2008 Cleveland BioLabs CEO to Present at Roth Capital 20th Annual OC Growth Stock Conference
Feb 19, 2008 Cleveland BioLabs Protectan CBLB502 Demonstrates Significant Reduction of Adverse Effects of Chemotherapeutic Drug in Mice
Feb 20, 2008 Cleveland BioLabs CEO to Present at 3rd Annual Stem Cell Summit in New York City
Mar 31, 2008 Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Mitigation Of Hematopoietic Damage at 48 Hours Post-Exposure to 6.5 Gy of Radiation
Apr 03, 2008 Department of Defense Awards Cleveland BioLabs Contract to Develop Protectan CBLB502
Apr 09, 2008 Cleveland BioLabs to Submit Protectan CBLB502 for BARDA BAA for Development of Therapies to Protect Civilian Population From Radiation Exposure
Apr 10, 2008 Science Magazine Publishes Cleveland BioLabs Breakthrough Paper on Protectan CBLB502's Radioprotective Activity
Apr 11, 2008 WBB Securities Upgrades Cleveland BioLabs to Strong Buy and Reiterates $13 Price Target
Apr 14, 2008 Cleveland BioLabs to Highlight Recent Achievements and Provide Update on Development Strategy on April 17 Conference Call
Apr 29, 2008 Cleveland BioLabs Management Reviews 2008 Highlights and Milestones at Annual Meeting
May 05, 2008 Cleveland BioLabs Featured in "Gene Marcial's 7 Commandments of Stock Investing"
May 07, 2008 Buyins.net Initiates Coverage on Cleveland BioLabs With SqueezeTrigger Price of $7.41
May 07, 2008 Cleveland BioLabs Completes Recruitment for Phase II Hormone-Refractory Prostate Cancer Trial
May 14, 2008 Cleveland BioLabs to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
May 29, 2008 Cleveland BioLabs Featured in Note From CEO of The Robins Group, LLC
Jul 08, 2008 Cleveland BioLabs Granted First Patent for Protectan CBLB502
Aug 07, 2008 Cleveland BioLabs Receives Notice of Allowance From FDA to Commence Clinical Testing With Protectan CBLB502
Aug 13, 2008 Cleveland BioLabs and Cleveland Clinic Demonstrate Accelerated Recovery of Limb Function With Protectan CBLB502 in Tourniquet Injury Model
Sep 12, 2008 National Institute of Allergy and Infectious Diseases Awards Cleveland BioLabs Grant for Protectan CBLB502 Research in Mitigation of Radiation Damage
Sep 16, 2008 Biomedical Advanced Research and Development Authority of the Department of Health and Human Services (BARDA) Awards Cleveland BioLabs Contract to Develop Protectan CBLB502
Sep 23, 2008 Cleveland BioLabs to Present Protectan CBLB502 at 2008 BARDA Day
Sep 29, 2008 Cleveland BioLabs to Present at Maxim Group Growth Conference
Oct 15, 2008 Cleveland BioLabs Doses First Healthy Volunteer in Initial Safety Study for Protectan CBLB502
Oct 21, 2008 Cleveland BioLabs to Present at 2008 BIO Investor Forum
Oct 24, 2008 Cleveland BioLabs Receives Letter From NASDAQ Citing Non-Compliance With Global Market Listing Requirements
Oct 27, 2008 Cleveland BioLabs Protectan CBLB612 Demonstrates Significant Reduction of Myelosuppression in Mouse Model of Chemotherapy
Nov 03, 2008 Cleveland BioLabs to Present at Rodman and Renshaw 10th Annual Healthcare Conference
Dec 01, 2008 Cleveland BioLabs Announces Appointment of International Expert in Chemical, Biological and Radiological/Nuclear Threat Countermeasures as Senior Vice President of Public Health and Government Services
Dec 29, 2008 Cleveland BioLabs Reports Advances in Curaxin Anticancer Program
Jan 20, 2009 Cleveland BioLabs Completes Dosing of Fourth Cohort in Initial Safety Study for Protectan CBLB502
Feb 17, 2009 Cleveland BioLabs Consummates Private Placement of Series D Preferred Stock and Common Stock Warrants
Mar 23, 2009 Cleveland Biolabs Consummates Private Placement of Series D Preferred Stock and Common Stock Warrants
Mar 25, 2009 Cleveland BioLabs to Host Investor Update Conference Call on March 31
Mar 30, 2009 Cleveland BioLabs Concludes Private Placement of Series D Preferred Stock and Common Stock Warrants
Apr 09, 2009 Cleveland BioLabs Updates Financial Condition Following Completion of Private Placement and Streamlining of Operations
May 15, 2009 Cleveland BioLabs Formally Terminates Boston Stock Exchange Listing
May 18, 2009 Oncogene Publishes Cleveland BioLabs Paper on Mechanism of Action of Curaxins
May 21, 2009 Cleveland BioLabs Signs Term Sheet for Joint Venture to Develop Curaxin Compounds for Cancer Applications
May 28, 2009 Cleveland BioLabs Submits Response to Department of Defense Sources Sought Notice for Radiological and Nuclear Medical Countermeasures
Jun 03, 2009 Cleveland BioLabs Concludes Initial Phase I Safety and Tolerability Study for CBLB502
Jun 25, 2009 Cleveland BioLabs Management Reviews Recent Highlights and Milestones at Annual Meeting
Jul 01, 2009 Department of Defense Releases Further Funding to Cleveland BioLabs Under $8.8 Million Contract for Development Studies on Protectan CBLB502
Aug 17, 2009 Cleveland BioLabs Receives First U.S. Patent Allowance for Its Radiation Protection Drug Protectan CBLB502
Aug 31, 2009 Cleveland BioLabs to Present at Rodman & Renshaw 11th Annual Global Healthcare Conference
Sep 08, 2009 Cleveland BioLabs to Present at NewsMakers in the Biotech Industry Conference
Sep 09, 2009 Cleveland BioLabs and Zhejiang Hisun Pharmaceutical Enter License Agreement for Protectan CBLB612 Hematopoietic Stem Cell Stimulator and Mobilizer in China
Sep 21, 2009 Cleveland BioLabs to Present at Maxim Group Growth Conference
Sep 22, 2009 National Institute of Allergy and Infectious Diseases Awards Cleveland BioLabs Additional Grant for Protectan CBLB502 Research in Mitigation of Radiation Damage
Sep 24, 2009 Cleveland BioLabs Receives $2.3 Million Addition to $13.3 Million Contract With Biomedical Advanced Research and Development Authority (BARDA) to Develop Radiation Countermeasure Protectan CBLB502
Sep 29, 2009 Cleveland BioLabs Awarded $5.3 Million Grand Opportunities Grant From National Institutes of Health for Protectan CBLB502 Research in Mitigation of Radiation Damage of GI Tract
Sep 30, 2009 Armed Forces Radiobiology Research Institute and Cleveland BioLabs Awarded Grant From Department of Defense to Study Radioprotective Effects of Protectan CBLB600 Series
Oct 05, 2009 Rodman & Renshaw Initiates Analyst Coverage of Cleveland BioLabs
Oct 06, 2009 Department of Defense Increases Ongoing Contract With Cleveland BioLabs for Developmental Studies Related to Protectan CBLB502
Oct 19, 2009 Cleveland BioLabs to Present at 8th Annual BIO Investor Forum
Oct 20, 2009 Cleveland BioLabs to Host Roundtable on Protectan CBLB502 for Acute Radiation Syndrome
Nov 02, 2009 Cleveland BioLabs to Present at Merriman 6th Annual Investor Summit
Nov 18, 2009 Cleveland BioLabs Publishes New Insights Into Mechanism of Action of Curaxins, Extending Their Clinical Potential
Nov 23, 2009 Cleveland BioLabs Opens Enrollment of Second Safety Study for CBLB502
Dec 22, 2009 Cleveland BioLabs President and CEO Reports Progress on Clinical and Corporate Developments
Dec 30, 2009 Cleveland BioLabs Establishes Joint Venture to Develop Curaxin Compounds for Cancer Applications
Jan 05, 2010 Cleveland BioLabs to Present at OneMedForum
Jan 06, 2010 Cleveland BioLabs Receives First U.S. Patent for Radiation Protection Drug CBLB502
Jan 12, 2010 Cleveland BioLabs to Respond to Department of Defense Request for Proposal for Radiation Countermeasure
Jan 19, 2010 Cleveland BioLabs Doses First Volunteers in Second Safety Study for CBLB502
Jan 27, 2010 Cleveland BioLabs to Present at 12th Annual BIO CEO & Investor Conference
Jan 28, 2010 Cleveland BioLabs Granted European Patent for Radiation Protection Drug CBLB502
Feb 17, 2010 Cleveland BioLabs Inc. to Host Press Conference on Radiation Countermeasure Developments for National Security and Oncologic Safety
Feb 24, 2010 Cleveland BioLabs Selects PharmaVigilant for Complex Phase I/II Oncology Study
Feb 26, 2010 Cleveland BioLabs Raises $5 Million From Institutional Investors Through Private Placement
Mar 04, 2010 Cleveland BioLabs Announces Annual Meeting
Mar 09, 2010 Cleveland BioLabs to Present at Roth Capital Partners 22nd Annual OC Growth Stock Conference
Apr 21, 2010 Cleveland BioLabs Chief Scientific Officer Presents at American Association for Cancer Research Meeting
Apr 26, 2010 Cleveland BioLabs to Provide Update on Development Progress and Corporate Strategy on May 4 Conference Call
Apr 26, 2010 Cleveland BioLabs Announces Launch of Incuron Joint Venture to Develop Curaxin Compounds
Apr 29, 2010 Biomedical Advanced Research and Development Authority (BARDA) Exercises Options on Cleveland BioLabs $15.6 Million Contract to Develop Radiation Countermeasure CBLB502
Apr 30, 2010 Cleveland BioLabs' Rachel Levine Interviewed by CorporateProfile.com
May 10, 2010 Cleveland BioLabs Concludes Dosing of Second Safety Study for CBLB502
May 11, 2010 Cleveland BioLabs to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
May 24, 2010 Cleveland BioLabs Adds Regulatory Affairs Expertise to Development Team
Jun 08, 2010 Cleveland BioLabs Management Shares Milestones and Progress Updates at Annual Meeti
Jun 15, 2010 Cleveland BioLabs to Present at Sidoti Microcap Conference
Jun 17, 2010 Cleveland BioLabs Chief Scientific Officer to Speak at Prestigious St. Petersburg International Economic Forum
Jun 28, 2010 Cleveland BioLabs Appoints Dr. Michael Paterno Director of Clinical Operations
Jul 20, 2010 Cleveland BioLabs Publishes New Study on Curaxins Indicating Potential Antiviral Applications
Jul 22, 2010 Cleveland Biolabs' CBLB502 for Reducing the Risk of Death Following Total Body Irradiation During or After a Radiation Disaster Granted Fast Track Status From FDA
Jul 29, 2010 Biomedical Advanced Research and Development Authority (BARDA) Exercises $4.1 Million Fourth Option on Cleveland BioLabs Contract to Develop Radiation Countermeasure CBLB502
Sep 07, 2010 Cleveland BioLabs to Present at Rodman & Renshaw 12th Annual Healthcare Conference
Sep 17, 2010 Department of Defense Awards Cleveland BioLabs Contract for CBLB502 Fully Valued at $45 Million
Sep 17, 2010 Cleveland BioLabs to Discuss Recent Developments on September 20 Conference Call
Sep 27, 2010 Cleveland BioLabs to Present at 9th Annual BIO Investor Forum
Sep 29, 2010 Cleveland BioLabs Announces Results of Second Safety Study for CBLB502
Oct 04, 2010 Cleveland BioLabs Granted First Patents for Protectan CBLB612
Oct 13, 2010 Cleveland BioLabs Files Registration Statement for Series B Class of Warrants
Oct 14, 2010 Cleveland BioLabs to Present at NewsMakers in the Biotech Industry Conference
Oct 19, 2010 Cleveland BioLabs Receives Notice of Patent Allowance From China for CBLB502
Nov 01, 2010 Cleveland BioLabs Announces Start of Phase IB Trial for Prototype Curaxin CBLC102 in Russia
Nov 02, 2010 Cleveland BioLabs and Incuron Receive $489,000 in Qualifying Therapeutic Discovery Project Grants
Nov 30, 2010 Cleveland BioLabs' CBLB502 Granted Orphan Drug Status From FDA for Prevention of Death Following a Potentially Lethal Dose of Total Body Irradiation During or After a Radiation Disaster
Dec 23, 2010 Cleveland BioLabs to Raise Approximately $8.39 Million in Registered Direct Offering With Single Institutional Investor
Jan 04, 2011 Cleveland BioLabs to Present at Sidoti Microcap Conference
Jan 20, 2011 Cleveland BioLabs Announces Potential Direct Anticancer Effect of CBLB502
Jan 25, 2011 Cleveland BioLabs Receives $1.6 Million Development Contract From Defense Threat Reduction Agency of Department of Defense for CBLB502
Feb 07, 2011 Cleveland BioLabs to Present at 13th Annual BIO CEO and Investor Conference
May 03, 2011 Cleveland BioLabs Nominates Former President of Roswell Park Cancer Institute to Board of Directors
May 09, 2011 Cleveland BioLabs Announces Annual Meeting
May 16, 2011 Cleveland BioLabs Announces New US Patent Allowances for CBLB502 and CBLB612
May 23, 2011 Cleveland BioLabs Receives Notice of Patent Allowance From Japan for CBLB502
May 31, 2011 Cleveland BioLabs Provides Update on CBLB502 and BARDA Development Contract
Jun 17, 2011 Cleveland BioLabs to Raise $23.5 Million in Registered Direct Offering
Jun 23, 2011 Cleveland BioLabs Closes $23.5 Million Registered Direct Offering
Jun 27, 2011 Cleveland BioLabs Added to Russell 3000(R) Index
Jun 30, 2011 Department of Defense Increases Development Contract With Cleveland BioLabs for CBLB502
Aug 08, 2011 Cleveland BioLabs to Host Quarterly Update Call on August 15
Aug 09, 2011 Cleveland BioLabs to Present at 2011 Wedbush Life Sciences Management Access Conference
Aug 10, 2011 Science Translational Medicine Publishes Breakthrough Finding From Cleveland BioLabs and Incuron on Identification of Target and Mechanism of Action of Novel Anticancer Agents Curaxins
Sep 01, 2011 Cleveland BioLabs Subsidiary Incuron Receives $5 Million Grant From Russian Federation Government Initiative
Sep 06, 2011 Cleveland BioLabs to Present at Rodman & Renshaw 13th Annual Healthcare Conference
Sep 26, 2011 Cleveland BioLabs and RUSNANO Enter Into Agreement to Form New Joint Venture to Develop Innovative Compounds for Cancer and Infectious Disease
Oct 03, 2011 Journal of Immunology Publishes Study of Cleveland BioLabs' Drug CBLB502 in Acute Renal Ischemic Failure
Oct 19, 2011 Cleveland BioLabs Announces Opening of New IND for CBLB502 in Cancer Patients
Oct 24, 2011 International Journal of Radiation Oncology, Biology and Physics Publishes Cleveland BioLabs Study of CBLB502 Protection From Radiation Dermatitis and Oral Mucositis in Head and Neck Cancer Model
Nov 01, 2011 Cleveland BioLabs to Host Quarterly Update Call on November 10
Dec 01, 2011 Cleveland BioLabs to Present at 4th Annual LD MICRO Growth Conference
Jan 17, 2012 Cleveland BioLabs Publishes Manuscript on New Radiation Countermeasure CBLB613
Jan 24, 2012 Cleveland BioLabs Announces Management Reorganization
Feb 06, 2012 Cleveland BioLabs to Present at 14th Annual BIO CEO and Investor Conference
Feb 16, 2012 Cleveland BioLabs Announces Science Publication on Molecular Mechanisms Underlying CBLB502's Interaction With TLR5
Mar 01, 2012 Cleveland BioLabs to Host Quarterly Update Call on March 14
Mar 12, 2012 Cleveland BioLabs Announces Start of Advanced Cancer Trial for CBLB502
Apr 03, 2012 Cleveland BioLabs Provides Update on BARDA Development Funding Process and Meetings With FDA
Apr 25, 2012 Cleveland BioLabs to Report First Quarter Financial Results and Provide Operational Update on May 3
Apr 30, 2012 Cleveland BioLabs and Incuron Announce Russian Regulatory Allowance of IND for Phase 1B Trial of CBLC137
May 03, 2012 Cleveland BioLabs Reports First Quarter 2012 Financial Results
May 07, 2012 Cleveland BioLabs Announces Annual Meeting and Investor Day on June 13
Jun 04, 2012 Cleveland BioLabs Reports Strong Survival Results Which Met the Primary Endpoint of Its GLP Efficacy Study With Radiation Countermeasure CBLB502
Jun 14, 2012 Cleveland BioLabs Reports Appointment of CEO and Provides Annual Stockholders' Meeting and Investor Day Updates
Jun 18, 2012 Cleveland BioLabs Launches Updated Website
Jun 21, 2012 Cleveland BioLabs and Incuron Announce Results of Studies of CBL0137 in Animal Models of Neuroblastoma
Jul 02, 2012 Cancer Prevention Research Publishes Preclinical Studies on Suppression of Breast Cancer Tumor Formation and Progression Using CBL0137
Jul 30, 2012 Cleveland BioLabs Signs Contract for Approximately $4 Million With Russian Ministry of Industry and Trade for Development of CBLB612
Jul 31, 2012 Cleveland BioLabs to Report Second Quarter Financial Results and Provide Operational Update on August 6
Aug 01, 2012 Cleveland BioLabs Announces Publication of Studies Identifying Biomarkers of CBLB502's Efficacy as a Radiation Countermeasure
Aug 06, 2012 Cleveland BioLabs Reports Second Quarter 2012 Financial Results and Development Progress
Aug 08, 2012 Cleveland BioLabs to Present at 2012 Wedbush Lifesciences Management Access Conference
Sep 04, 2012 Cleveland BioLabs to Present at Rodman and Renshaw 14th Annual Healthcare Conference
Sep 10, 2012 Cleveland BioLabs Receives FDA Agreement on Pivotal Animal Efficacy Studies for Development of CBLB502 (Entolimod™) as Radiation Countermeasure
Oct 01, 2012 Cleveland BioLabs Receives FDA Meeting Minutes and Advice Letter on Clinical Protocol for Development of Entolimod™ (CBLB502) as Radiation Countermeasure
Oct 02, 2012 Cleveland BioLabs and Incuron Announce CBL0102 Orphan Drug Status for Hepatocellular Carcinoma
Oct 04, 2012 Department of Defense Defense Threat Reduction Agency Increases Development Contract With Cleveland BioLabs for Entolimod™ (CBLB502)
Oct 10, 2012 Cleveland BioLabs and Incuron Announce Start of Phase 1 Trial for CBL0137
Oct 18, 2012 Cleveland BioLabs Submits Proposal to BARDA for Development Funding for Entolimod(TM) (CBLB502)
Oct 18, 2012 Cleveland BioLabs Announces Proposed Public Offering of Common Stock and Warrants
Oct 19, 2012 Cleveland BioLabs Prices $15 Million Public Offering of Common Stock and Warrants
Oct 25, 2012 Department of Defense Chemical Biological and Medical Systems Continues Funding Under Development Contract With Cleveland BioLabs for Entolimod(TM) (CBLB502)
Oct 30, 2012 Cleveland BioLabs to Report Third Quarter Financial Results and Provide Operational Update on November 8
Nov 06, 2012 Cleveland BioLabs Announces Publication of Studies on Effect of Entolimod(TM) (CBLB502) on Graft-Versus-Tumor Activity in Models of Allogeneic Bone Marrow Transplantation
Nov 08, 2012 Cleveland BioLabs Reports Third Quarter 2012 Financial Results and Development Progress
Nov 27, 2012 Panacela Labs, a Subsidiary of Cleveland BioLabs, Signs Contract for Approximately $4.6 Million With Russian Ministry of Industry and Trade for Development of Xenomycins
Dec 04, 2012 Cleveland BioLabs to Present at Oppenheimer 23rd Annual Healthcare Conference
Jan 24, 2013 Cleveland BioLabs to Present at BARDA and NIAID Sponsored Symposium on Development of Radiation Medical Countermeasures
Feb 05, 2013 Cleveland BioLabs to Present at 15th Annual BIO CEO and Investor Conference
Mar 08, 2013 Cleveland BioLabs to Report Fiscal 2012 Financial Results and Provide Operational Update on March 14
Mar 14, 2013 Cleveland BioLabs Reports Fourth Quarter and Fiscal 2012 Financial Results and Development Progress
Apr 02, 2013 Cleveland BioLabs and Incuron Announce Notice of Allowance From FDA to Commence Clinical Testing With CBL0137
Apr 08, 2013 Cleveland BioLabs Strengthens Clinical Development Team
Apr 23, 2013 Cleveland BioLabs Announces Changes to Board of Directors
Apr 30, 2013 Cleveland BioLabs to Report First Quarter 2013 Financial Results and Provide Operational Update on May 9
May 01, 2013 Cleveland BioLabs, Roswell Park Announce Publication of Studies Defining Role of Liver in Activity of Entolimod (CBLB502)
May 08, 2013 Cleveland BioLabs Announces Appointment of Shareholder Representative to Board
May 09, 2013 Cleveland BioLabs Reports First Quarter 2013 Financial Results and Development Progress
May 09, 2013 CORRECTION -- Cleveland BioLabs Reports First Quarter 2013 Financial Results and Development Progress
May 14, 2013 Cleveland BioLabs and Incuron Announce US and European Patent Allowances for Curaxins
Jun 25, 2013 Cleveland BioLabs and Incuron Announce Poster Presentation at ESMO 15th World Congress on Gastrointestinal Cancer
Jul 08, 2013 Cell Reports Publication Elucidates Role of FACT as Accelerator of Tumor Transformation and Potential Marker and Target of Aggressive Cancers
Aug 01, 2013 Cleveland BioLabs to Report Second Quarter 2013 Financial Results and Provide Operational Update on August 13
Aug 07, 2013 Cleveland BioLabs and Incuron Announce Start of US Trial With CBL0137
Aug 13, 2013 Cleveland BioLabs Reports Second Quarter 2013 Financial Results and Development Progress
Sep 12, 2013 Cleveland BioLabs and Incuron Announce Poster Presentation at 2013 ASCP Annual Meeting
Sep 19, 2013 Cleveland BioLabs and Incuron Announce Poster Presentation at 2013 European Cancer Congress
Oct 01, 2013 Cleveland BioLabs Secures $10 Million Loan Agreement With Hercules Technology Growth Capital
Oct 02, 2013 Cleveland BioLabs and Incuron Announce Poster Presentation at Cell Symposia: Cancer Epigenomics
Oct 16, 2013 Cleveland BioLabs Signs Contract With Russian Ministry of Industry and Trade for Clinical Development of Entolimod (CBLB502)
Oct 18, 2013 Cleveland BioLabs Optimizes Operational Focus on Clinical Development
Oct 23, 2013 Panacela Signs Contract for Approximately $4.6 Million With Russian Ministry of Industry and Trade for Development of Mobilan; Announces Appointment of Michael Fonstein as CEO and President
Oct 29, 2013 Cleveland BioLabs to Report Third Quarter 2013 Financial Results and Provide Operational Update on November 6
Nov 06, 2013 Cleveland BioLabs Reports Third Quarter 2013 Financial Results and Development Progress
Nov 21, 2013 Cleveland BioLabs and Incuron Announce Poster Presentation at Society of Neuro-Oncology Meeting
Dec 03, 2013 Cleveland BioLabs to Present at Oppenheimer 24th Annual Healthcare Conference
Dec 18, 2013 Cleveland BioLabs Announces Departure of Jean Viallet to Assume Oncology Development Leadership Role at Leading Biopharmaceutical Company
Jan 14, 2014 Cleveland BioLabs Announces $7 Million At-The-Market Registered Direct Offering
Jan 23, 2014 Cleveland BioLabs Provides Update on Barda Development Proposal
Feb 04, 2014 Cleveland BioLabs to Present at 2014 BIO CEO & Investor Conference
Feb 27, 2014 Cleveland BioLabs to Report Fourth Quarter and Fiscal 2013 Financial Results and Provide Operational Update on March 11
Mar 10, 2014 Cleveland BioLabs to Host Fourth Quarter Earnings Webcast Live on Tuesday, March 11, 2014
Mar 11, 2014 Cleveland BioLabs Reports Fourth Quarter and Fiscal 2013 Financial Results and Development Progress
Apr 01, 2014 CBL0137 Combination Studies to Be Presented at 2014 AACR Annual Meeting
Apr 16, 2014 Cleveland BioLabs Announces the Successful Completion of a Phase 1 Study of CBL0102
Apr 29, 2014 Cleveland BioLabs to Report First Quarter 2014 Financial Results and Provide Operational Update on May 8
May 08, 2014 Cleveland BioLabs Reports First Quarter 2014 Financial Results and Development Progress
May 09, 2014 Cleveland BioLabs Announces Compensation Reductions for Co-Founders and Directors; New Board Nominees
Jun 18, 2014 Cleveland BioLabs Reduces Debt With $3.5 Million At-the-Market Private Placement of Unregistered Stock
Jul 29, 2014 Cleveland BioLabs to Report Second Quarter 2014 Financial Results and Provide Operational Update on August 7
Aug 06, 2014 Cleveland BioLabs to Host Second Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, August 7, 2014
Aug 07, 2014 Cleveland BioLabs Reports Second Quarter 2014 Financial Results and Development Progress
Sep 02, 2014 Cleveland BioLabs to Present at Rodman & Renshaw 16th Annual Global Investment Conference
Sep 02, 2014 Cleveland BioLabs to Report Outcome of July FDA Meeting and Host Conference Call on September 3
Sep 03, 2014 Cleveland BioLabs Announces Green Light to Submit Pre-Emergency Use Authorization Application for Entolimod
Sep 08, 2014 Cleveland BioLabs and Sabby Announce Resolution of Litigation
Sep 15, 2014 Cleveland BioLabs Announces Approval to Start Phase 1 Study for Hematopoietic Stem Cell Mobilizer CBLB612 in Russian Federation
Oct 28, 2014 Cleveland BioLabs to Report Third Quarter 2014 Financial Results and Provide Operational Update on November 5
Nov 04, 2014 Cleveland BioLabs to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Wednesday, November 5, 2014
Nov 05, 2014 Cleveland BioLabs Reports Third Quarter 2014 Financial Results and Development Progress
Nov 13, 2014 Cleveland BioLabs and Roswell Park Cancer Institute Announce Publication of Studies Demonstrating Curaxin CBL0137's Ability to Eradicate Drug-Resistant Cancer Stem Cells and Potentiate Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
Jan 06, 2015 Cleveland BioLabs and Incuron Announce Updates on Clinical Progress With Curaxin CBL0137
Jan 12, 2015 Cleveland BioLabs Receives Department of Defense Support to Further Development of Entolimod (CBLB502) as a Medical Radiation Countermeasure
Jan 27, 2015 Cleveland BioLabs Announces Results of Special Meeting of Stockholders and Reverse Stock Split
Jan 28, 2015 Cleveland BioLabs Announces Board Appointment
Jan 29, 2015 Cleveland BioLabs Announces Oncology Clinical Development Update for Entolimod
Feb 04, 2015 Cleveland BioLabs Announces $4.2 Million Financing
Feb 05, 2015 Cleveland BioLabs to Present at 2015 BIO CEO & Investor Conference
Feb 10, 2015 Cleveland BioLabs Announces Annual Meeting
Feb 11, 2015 Cleveland BioLabs Announces Expansion of Entolimod Patent Portfolio With New Composition of Matter Patents
Feb 17, 2015 Cleveland BioLabs to Report Fourth Quarter and Fiscal Year 2014 Financial Results on February 24
Feb 18, 2015 Cleveland BioLabs Announces Receipt of Letter From NASDAQ Confirming Compliance With Minimum Bid Price Requirement
Feb 23, 2015 Cleveland BioLabs to Host Fourth Quarter and Fiscal Year 2014 Earnings Conference Call and Webcast Live on Tuesday, February 24, 2015
Feb 24, 2015 Cleveland BioLabs Reports Fourth Quarter and Fiscal 2014 Financial Results and Development Progress
Mar 02, 2015 Cleveland BioLabs and Incuron Announce Growth of Curaxin CBL0137 Patent Portfolio With U.S. Composition of Matter Patent
Mar 16, 2015 Cleveland BioLabs Announces Completion of Dosing in Phase 1 Study of CBLB612 in Russian Federation
Apr 02, 2015 Cleveland BioLabs Announces New U.S. Composition of Matter Patent for CBLB612
Apr 14, 2015 Cleveland BioLabs Receives Funding Recommendation From Department of Defense for Additional Development Proposal for Entolimod (CBLB502) as a Medical Radiation Countermeasure
Apr 22, 2015 Cleveland BioLabs Announces Acceptance of Entolimod Phase 1 Study Findings for Poster Presentation at ASCO
Apr 27, 2015 Cleveland BioLabs and Roswell Park Cancer Institute Announce Award of Department of Defense Breast Cancer Research Program Breakthrough Grant for Entolimod
Apr 29, 2015 Cleveland BioLabs Enters Into Agreement to Raise Up to $4 Million Through Sales of Equity Stake in Incuron Joint Venture
Apr 30, 2015 Cleveland BioLabs to Report First Quarter 2015 Financial Results on May 6
May 05, 2015 Cleveland BioLabs Announces Appointment of Biotechnology Industry Veteran, Langdon Miller, MD, as President and Chief Medical Officer
May 06, 2015 Cleveland BioLabs Reports First Quarter 2015 Financial Results and Development Progress
Jun 01, 2015 Cleveland BioLabs Releases Entolimod Phase 1 Study Findings at ASCO
Jun 15, 2015 Cleveland BioLabs Submits Pre-EUA Dossier for Entolimod to FDA
Jun 25, 2015 Cleveland BioLabs Enters Into Private Placement Agreement With Strategic Investor for $25 Million Equity Financing
Jul 09, 2015 Cleveland BioLabs Closes Private Placement With Strategic Investor for $25 Million Equity Financing
Jul 10, 2015 Cleveland BioLabs Announces Board Appointments
Jul 13, 2015 Cleveland BioLabs Announces Results of Phase 1 Study of CBLB612 in Russian Federation
Jul 16, 2015 Cleveland BioLabs Announces Receipt of Letter From Nasdaq Confirming Compliance With Minimum Stockholders' Equity Requirement
Jul 21, 2015 Cleveland BioLabs to Report Second Quarter 2015 Financial Results on August 3
Jul 31, 2015 Cleveland BioLabs Announces Date Change for Second Quarter 2015 Financial Results
Aug 12, 2015 Cleveland BioLabs Reports Second Quarter 2015 Financial Results and Development Progress
Aug 18, 2015 Cleveland BioLabs Announces New Patents Strengthening Entolimod Portfolio
Sep 02, 2015 Cleveland BioLabs to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Sep 02, 2015 Department of Defense Awards Cleveland BioLabs a $9.2 Million Contract for Advanced Development of Entolimod as a Medical Radiation Countermeasure
Sep 16, 2015 Cleveland BioLabs Announces Publication of Studies Demonstrating Efficacy of Entolimod as a Radiation Countermeasure up to 48 Hours After Exposure of Nonhuman Primates to Lethal Radiation
Sep 21, 2015 Department of Defense Grants Cleveland BioLabs Second Award for Advanced Development of Entolimod as a Medical Radiation Countermeasure
Oct 27, 2015 Cleveland BioLabs to Report Third Quarter 2015 Financial Results on November 5
Nov 05, 2015 Cleveland BioLabs Reports Third Quarter 2015 Financial Results and Development Progress
Nov 30, 2015 Cleveland BioLabs Announces Expanded U.S. Patent Protection for Entolimod
Dec 14, 2015 Entolimod Shown to Suppress Liver Metastases in Model of Ocular Melanoma in Collaborative Study by Cleveland BioLabs, Emory University and Roswell Park Cancer Institute
Dec 22, 2015 Cleveland BioLabs and Rusnano Make Additional Investments in Panacela
Jan 21, 2016 Cleveland BioLabs Attains Orphan Drug Status From the EMA for Entolimod as a Radiation Countermeasure
Jan 26, 2016 Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation
Feb 02, 2016 Cleveland BioLabs Announces Start of Colorectal Cancer Study of Entolimod in Russian Federation
Feb 09, 2016 Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis in Studies by Cleveland BioLabs and Roswell Park Cancer Institute
Feb 22, 2016 Cleveland BioLabs Reports 2015 Financial Results and Development Progress
Mar 16, 2016 Cleveland BioLabs Provides Update on Pre-EUA Review of Entolimod as Radiation Countermeasure
Apr 04, 2016 Cleveland BioLabs Announces Webcast of Annual Meeting
May 16, 2016 Cleveland BioLabs Reports First Quarter 2016 Financial Results and Development Progress
Jul 12, 2016 Cleveland BioLabs Announces Board Resignations
Aug 15, 2016 Cleveland BioLabs Reports Second Quarter 2016 Financial Results and Development Progress
Oct 11, 2016 Cleveland BioLabs Announces a $1.1 Million Cost Realignment With the Department of Defense
Nov 14, 2016 Cleveland BioLabs Reports Third Quarter 2016 Financial Results and Development Progress
Feb 22, 2017 Cleveland BioLabs Reports 2016 Financial Results and Development Progress
Apr 11, 2017 Cleveland BioLabs Announces Webcast of Annual Meeting
Apr 17, 2017 Cleveland BioLabs Announces European Medicines Agency Positive Opinion Regarding the Entolimod Pediatric Investigation Plan
Apr 17, 2017 Cleveland BioLabs Announces Commencement of In Vivo Biocomparability Study
May 15, 2017 Cleveland BioLabs Reports First Quarter 2017 Financial Results and Development Progress
Aug 14, 2017 Cleveland BioLabs Reports Second Quarter 2017 Financial Results and Development Progress
Nov 14, 2017 Cleveland BioLabs Reports Third Quarter 2017 Financial Results and Development Progress
Mar 06, 2018 Cleveland Biolabs Reports 2017 Financial Results and Development Progress
Mar 28, 2018 Cleveland Biolabs Announces Progress on European Marketing Authorization Application
May 15, 2018 Cleveland Biolabs Reports First Quarter 2018 Financial Results and Development Progress
Aug 06, 2018 Cleveland BioLabs Announces Delay in Analysis of Biocomparability Data Required for Regulatory Submission
Aug 14, 2018 Cleveland Biolabs Announces Formation and Financing of an Anti-Aging Joint Venture
Aug 14, 2018 Cleveland Biolabs Reports Second Quarter 2018 Financial Results And Development Progress
Nov 14, 2018 Cleveland Biolabs Reports Third Quarter 2018 Financial Results and Development Progress
Mar 07, 2019 Cleveland Biolabs Reports 2018 Financial Results and Development Progress
May 15, 2019 Cleveland Biolabs Reports First Quarter 2019 Financial Results and Development Progress
Aug 14, 2019 Cleveland Biolabs Reports Second Quarter 2019 Financial Results and Development Progress
Nov 14, 2019 Cleveland BioLabs Reports Third Quarter 2019 Financial Results and Development Progress
May 15, 2020 Cleveland BioLabs Reports First Quarter 2020 Financial Results and Development Progress
Jun 01, 2020 Cleveland BioLabs Announces $3.175 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Jun 03, 2020 Cleveland BioLabs Closes $3.175 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
Oct 19, 2020 Cytocom and Cleveland BioLabs Announce Definitive Merger Agreement
Feb 17, 2021 Cleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc.
Feb 19, 2021 Cleveland BioLabs, Inc. Announces $14 Million Registered Direct Offering of Common Stock
Feb 23, 2021 Cleveland BioLabs, Inc. Announces Closing of $14 Million Registered Direct Offering of Common Stock
Apr 14, 2021 Genome Protection Announces Publication of the Next Generation Deimmunized TLR5 Agonist, GP532

Headquarters:
Cleveland BioLabs, Inc.
73 High Street
Buffalo, NY 14203
Tel: 716-849-6810
Fax: 716-849-6820
View Map

Terms of Use

The Site has been designed to provide general information about Cleveland BioLabs, Inc.. The following Terms of Use set forth the terms and conditions upon which you may access and use the Site and the information and content made available through the Site. Please read them carefully. By accessing or using the Site, you signify that you have read, understand, accept and agree to be bound by these Terms of Use and intend these Terms of Use to be the legal equivalent of a signed, written contract. IF YOU DO NOT ACCEPT, AND AGREE TO BE BOUND BY, THESE TERMS OF USE, PLEASE DO NOT ACCESS OR USE THE SITE.

Permission to Use

Cleveland BioLabs grants you a personal, revocable, nonexclusive, nontransferable license to access and use the Site in accordance with these Terms of Use. Your right to access and use the Site is expressly conditioned on your continued compliance with these Terms of Use.

Reservation of Right to Modify or Terminate Terms of Use

Cleveland BioLabs reserves the right to modify these Terms of Use or to impose new or additional terms of use at any time (“Modified Terms”). Modified Terms may be incorporated into these Terms of Use by any reasonable means (including, without limitation, by posting them to the Site). Your continued use of the Site following the incorporation of any such Modified Terms shall be deemed conclusively to indicate your acceptance of all such Modified Terms. In addition, Cleveland BioLabs may, in its sole discretion, terminate these Terms of Use or your right to access the Site at any time for any reason (including, without limitation, improper use of the Site or failure to adhere to these Terms of Use) or for no reason. Termination of these Terms of Use will not affect in any way Cleveland BioLabs’ rights to relief at law or in equity.

Intellectual Property Rights

All content of the Site is protected under United States copyright and trademark law, as well as other state, national, and international laws and regulations. You may download, store, print and copy selected information on the Site for your personal noncommercial use, provided that: (i) all hard copies of any such information include all copyright and other applicable notices included with such information on the Site; (ii) you do not modify, alter or adapt the content of the Site in any way or delete or modify any copyright or trademark notice contained on the Site; and (iii) you do not reverse engineer, decompile or disassemble any aspect of the Site. CLEVELAND BIOLABS, INC., INCURON, PANECELA and other Cleveland BioLabs logos and product names included on the Site are the trademarks of Cleveland BioLabs. All other product and service names contained on the Site, if any, are the trademarks or service marks of their respective owners. Except as expressly provided herein, nothing in these Terms of Use or on the Site shall be construed as granting any license or right to use any copyright, trademark or other intellectual property right of Cleveland BioLabs, by implication, estoppel or otherwise. All rights not expressly granted in these Terms of Use are hereby reserved.

Certain Site Content

Any health or medical information included on the Site is for informational purposes only and is not, and is not intended to be, a medical diagnosis or a replacement for advice given by a physician or other healthcare professional, and none of the information included on the Site constitutes, or is intended to constitute, investment advice. Product candidates in development described on the Site have not been found safe or effective by any regulatory agency and are not approved for any use other than in certain clinical trials. Information included on the Site regarding any product approved for marketing is qualified in its entirety by reference to the full prescribing information for such product.

Third-Party Information

The Site may include certain third-party information or content. This third-party information or content does not represent the views, opinions or beliefs of Cleveland BioLabs, and Cleveland BioLabs disclaims any responsibility for any such third-party information or content.

Forward-Looking Statements

This Site contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors.

These factors include, among others, the Company’s history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern; the Company’s need for substantial additional financing to meet its business objectives; the potential for the loss of funding from the Company’s R&D grants and contracts and its ability to win additional funding under such grants and contracts; the Company’s failure to successfully and timely develop new products; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company’s inability to obtain regulatory approval in a timely manner or at all; the Company’s collaborative relationships and the financial risks related thereto; the Company’s ability to comply with its obligations under license agreements; the potential for significant product liability claims; and the Company’s ability to comply with various safety, environmental and other governmental regulations. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the “Risk Factors” and “Forward-Looking Statements” described in the Company’s periodic filings with the Securities and Exchange Commission.

Submissions

You may use the Site to contact Cleveland BioLabs with inquiries about information included on the Site. When you provide any information to Cleveland BioLabs, you agree to provide true, accurate, complete and current information and not to use a false or misleading name or a name that you are not authorized to use. You shall not transmit information to or through the Site that: (i) infringes or violates any intellectual property right or privacy right of any third party; or (ii) contains confidential information or trade secrets belonging to you or any third party. Cleveland BioLabs does not want to receive any such information. Any ideas, suggestions, information, know-how, material or other content transmitted to or through the Site will be deemed to include a royalty-free, perpetual, irrevocable, transferable, worldwide, nonexclusive right and license for Cleveland BioLabs to adopt, publish, reproduce, disseminate, transmit, distribute, copy, use, create derivative works, display, (in whole or part), or act thereon without any approval or consideration from you, in any form, medium, or technology now known or later developed for the full term of any rights that may exist therein. Cleveland BioLabs makes no promise, express or implied, that it will not use any such idea, suggestion, information, know-how, material or other content for its own purposes, which may include reproduction, publication, broadcast and posting.

Links

The Site may provide hypertext links to other web sites that are not owned or controlled by Cleveland BioLabs. These links are provided for your convenience only. These web sites are controlled by third parties that Cleveland BioLabs does not control. Accordingly, Cleveland BioLabs expressly disclaims any responsibility for the content of such web sites, for the accuracy or reliability of the information thereon and for the quality of products or services provided thereby or advertised thereon. No link included on the Site constitutes an endorsement of Cleveland BioLabs of any content of, information on or product or service provided by, or advertised on, any such web site. If you choose to hyperlink to another web site, you do so at your own risk. Cleveland BioLabs reserves the right to terminate any hypertext link without notice.

Security

You are prohibited from violating or attempting to violate the security of the Site. Without limiting the generality of the foregoing, you may not: (i) access data or materials that are not intended for you; (ii) log, or attempt to log, into a server or account that you are not authorized to access; or (iii) attempt to probe, scan or test the vulnerability of the Site. Violations of system or network security may result in civil or criminal liability. Cleveland BioLabs reserves the right to investigate any suspected violation of this section and to involve and cooperate with law enforcement authorities in prosecuting any party who participates in any such violation.

Compliance with Laws

You may use the Site only for lawful purposes. You agree that you will, at all times, comply with all applicable local, state, national and international laws, statutes, rules, regulations, ordinances and the like applicable to your use of the Site.

Disclaimers; Limitation of Liability

THE SITE IS PROVIDED “AS IS” AND “AS AVAILABLE,” WITHOUT WARRANTIES OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE BY LAW, CLEVELAND BIOLABS DISCLAIMS ALL WARRANTIES, EXPRESS, IMPLIED OR STATUTORY (INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT).

Cleveland BioLabs does not warrant that the Site will be uninterrupted, secure or error-free, that defects will be corrected, or that the Site or the server that makes it available are or will be free of viruses or other harmful components. Information included on the Site may be incomplete, outdated or inaccurate and may contain typographical errors. Cleveland BioLabs makes no commitment to update the information included on the Site. YOUR USE OF THE SITE IS AT YOUR OWN RISK. UNDER NO CIRCUMSTANCES SHALL CLEVELAND BIOLABS OR ANY OF ITS DIRECTORS, OFFICERS, EMPLOYEES, OR AGENTS BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL OR EXEMPLARY DAMAGES (INCLUDING DAMAGES FOR LOSS OF BUSINESS, REVENUE OR PROFITS AND THE LIKE) ARISING OUT OF OR IN CONNECTION WITH YOUR USE OF THE SITE OR YOUR RELIANCE ON ANY INFORMATION CONTAINED ON THE SITE, WHETHER BASED ON CONTRACT, NEGLIGENCE, TORT, STRICT LIABILITY OR ANY OTHER BASIS, EVEN IF CLEVELAND BIOLABS HAS BEEN ADVISED OF, OR SHOULD HAVE KNOWN OF, THE POSSIBILITY OF SUCH DAMAGES. Because some jurisdictions do not permit the exclusion of certain warranties or the limitation of liability as set forth above, such exclusions and limitations may not apply to you.

Jurisdiction

The information provided on the Site is intended for United States audiences only. Cleveland BioLabs makes no representation that the information on the Site is appropriate or available for use in other locations, and access or use of the Site from territories in which the content of the Site may be illegal is prohibited. If you wish to access or use the Site from outside of the United States, you do so on your own initiative and you are responsible for complying with applicable laws and regulations. You should not construe anything on the Site as a promotion of, or solicitation for, any product or product candidate that is not authorized by the laws and regulations of the country in which you are located.

Other Agreements

These Terms of Use set forth the terms and conditions upon which you may access and use the Site and the information and content included on, or made available through, the Site. These Terms of Use do not modify, alter or amend any other agreement that you may have or may enter into in the future with Cleveland BioLabs.

Miscellaneous

These Terms of Use constitute the entire agreement between you and Cleveland BioLabs with respect to your access to, and use of, the Site and the information and content included on, or made available through, the Site. The failure of Cleveland BioLabs to exercise or enforce any right or provision of these Terms of Use shall not constitute a waiver of such right or provision. If any provision of these Terms of Use is found by a court of competent jurisdiction to be invalid, the remaining provisions of these Terms of Use shall remain in full force and effect.

Privacy Policy

We respect the privacy of our visitors to our website, the home page of which is located at www.cbiolabs.com. This Privacy Policy is intended to inform you of our policies and practices regarding the collection, use and disclosure of any personal information you submit to us through our website. “Personal Information” is information about you that is personally identifiable like your name, address, email address, or phone number, and other information that is not otherwise publicly available.

User Consent

By submitting Personal Information through our website, you agree to the terms of this Privacy Policy.

Collection of Personal Information

We collect Personal Information that you submit to us voluntarily through our website. The types of Information we collect are:

For visitors who email us directly via an email hyperlink:

  • Email address
  • Any content included in the email

For all visitors:

  • As you navigate our website, certain passive information will also be collected, including Internet Protocol addresses, cookies and navigational data. This type of information will be used for the purposes of gathering data to provide improved administration of our website, and to improve the quality of your experience when interacting with our website.

Use of Personal Information

In general, Personal Information you submit to us is used either to respond to requests that you make, or to aid us in serving you better.

Disclosure of Personal Information

We do not sell your Personal Information or share your information with other companies or organizations without your consent. The content of any communications you send to us is non-confidential, and we are under no obligation to refrain from reproducing, publishing, or otherwise using such content in any way or for any purpose. We will not reproduce, publish, or otherwise use your Personal Information in connection with such content. We may, however, reproduce or use your Personal Information in connection with any resume you submit to us for employment recruiting purposes. We are free to use the content of any such communications (excluding any resume you submit to us), including any ideas, inventions, concepts, techniques, or know-how disclosed therein, for any purpose including developing, manufacturing, and/or marketing goods or services.

Although we currently do not have a parent company, any subsidiaries, joint ventures, or other companies under a common control (collectively, “affiliates”), we may in the future. We may share some or all of your Personal Information with these affiliates, in which case we will require our affiliates to honor this Privacy Policy. If we are acquired by another company, that company will possess the Personal Information collected by us and it will assume the rights and obligations regarding your Personal Information as described in this Privacy Policy.

Regarding Children

Our website is not designed for children under the age of 13. We will not deliberately gather Personal Information about visitors in this age group, and do not collect any information on this website with respect to age.

Links to Other Sites

Our provision of a link to any other website or location is for your convenience and does not signify our endorsement of such other website or location or its contents. We have no control over, do not review, and cannot be responsible for, these outside websites or their content. Please be aware that the terms of our Privacy Policy does not apply to these outside websites.

Data Security

We use industry-standard methods to secure the communication of Personal Information from your computer to our servers. In addition, we use industry-standard methods of securing our databases of Personal Information, including the use of firewalls. Except as provided elsewhere in this Privacy Policy, we limit access to Personal Information databases to those persons in our organization who have a business need for such access. You should know, however, that no company, including Cleveland BioLabs, can fully eliminate security risks associated with Personal Information.

Contact Us

Should you have any questions or concerns regarding this Privacy Policy, please contact us:

Cleveland BioLabs, Inc.
73 High St.
Buffalo, NY 14203
(716) 849-6810

Privacy Policy Updates

This Privacy Policy is subject to occasional revision, and any changes will be posted on this site. If you object to any such changes, you must cease using our website. Continued use of our website following notice of any such changes shall indicate your acknowledgement of such changes and agreement to be bound by the terms and conditions of such changes.

This policy was last updated on June 15, 2012.